Concurrence of nivolumab ‐induced interstitial lung disease and cancer invasion

In conclusion, nivolumab‐related ILD and cancer invasion may concur and aggressive biopsy should be considered if nivolumab‐related ILD is refractory to immunosuppressive therapy. Nivolumab‐related intersitital lung disease (ILD) may concur with cancer invasion in non‐small‐cell lung cancer (NSCLC) patients. These conditions are difficult to distinguish from each other by computed tomography (CT) findings, and in such cases, aggressive biopsy should be considered.
Source: Respirology Case Reports - Category: Respiratory Medicine Authors: Tags: Case Report Source Type: research